Back to search results

A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig MEDI5752 as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy eVOLVE-HNSCC

Brief Summary

Type:
Head and Neck Cancers

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT06129864

Study #:
STUDY00160134

Start Date:
May 08, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06129864

View Complete Trial Details & Eligibility at ClinicalTrials.gov